Claim Details: Submit your information here: https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-incinvestigation. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. To speak with an attorney for more information visit: Why Bleichmar Fonti & Auld LLP? https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation N ...

On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to close in the middle of 2024. BFA is currently investigating the go private transaction and believes that Cerevel ...

The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. LOS ANGELES, June 20, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation. Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction ...

Claim Details: BFA is currently investigating the go private transaction and believes that Cerevel Therapeutics' board of directors was conflicted, engaged in an unfair process, and agreed to an unfair amount to be paid to shareholders. If you are a current shareholder, you are encouraged to submit your information to find out about your rights. Next Steps: All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigatio ...

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation. On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will a ...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation. On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will a ...

On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to close in the middle of 2024. If you currently own shares of Cerevel Therapeutics you may have legal options and ...

A downtrend has been apparent in Cerevel Therapeutics Holdings, Inc. (CERE) lately with too much selling pressure. The stock has declined 5.1% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used ...

Claim Details: Submit your information here: https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-incinvestigation. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. To speak with an attorney for more information visit: Why Bleichmar Fonti & Auld LLP? https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation N ...